

November 24, 2015


## STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (CD-139)	NAQUOTINIB
PRONUNCIATION	na kwoe' ti nib
THERAPEUTIC CLAIM	Treatment of advanced non-small cell lung cancer

## CHEMICAL NAMES

1. 2-Pyrazinecarboxamide, 6-ethyl-3-[[4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-5-[[[(3*R*)-1-(1-oxo-2-propen-1-yl)-3-pyrrolidinyl]oxy]-
2. 6-ethyl-3-({4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-{{[(3*R*)-1-(1-oxoprop-2-en-1-yl)pyrrolidin-3-yl]oxy}pyrazine-2-carboxamide
3. 6-Ethyl-3-{4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino}-5-{{[(3*R*)-1-(prop-2-enoyl)pyrrolidin-3-yl]oxy}pyrazine-2-carboxamide

## STRUCTURAL FORMULA



MOLECULAR FORMULA	C <sub>30</sub> H <sub>42</sub> N <sub>8</sub> O <sub>3</sub>
MOLECULAR WEIGHT	562.7
TRADEMARK	None as yet
SPONSOR	Astellas Pharma Global Development, Inc.
CODE DESIGNATIONS	ASP8273
<u>CAS</u> REGISTRY NUMBER	1448232-80-1
UNII	47DD4548PB
WHO NUMBER	10317
gbk	